scispace - formally typeset
T

Tito R. Mendoza

Researcher at University of Texas MD Anderson Cancer Center

Publications -  288
Citations -  20415

Tito R. Mendoza is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Cancer pain. The author has an hindex of 62, co-authored 263 publications receiving 17679 citations. Previous affiliations of Tito R. Mendoza include University of Wisconsin-Madison & University of Texas at Austin.

Papers
More filters
Journal ArticleDOI

Validation Study of the Korean Version of the M. D. Anderson Symptom Inventory

TL;DR: Discriminant validity of the MDASI-K was demonstrated by its ability to clearly distinguish significant differences within different Eastern Cooperative Oncology Group performance statuses and those between the patient and normal groups in the mean scores of both symptom and interference.
Journal ArticleDOI

Assessment of clinical relevant fatigue level in cancer

TL;DR: “Usual fatigue” was a sensitive and reliable indicator of fatigue severity and was defined as mild, moderate, or severe (8–10) because it had the strongest correlation with the functional interference, symptoms, depression, and QOL.
Journal ArticleDOI

Russian Brief Pain Inventory: Validation and Application in Cancer Pain

TL;DR: The Russian version of the Brief Pain Inventory (BPI-R) is psychometrically sound in its reliability and validity and predicts inadequate pain management in a multivariate logistic regression model.
Journal ArticleDOI

Brief cognitive-behavioral audiotape interventions for cancer-related pain: Immediate but not long-term effectiveness.

TL;DR: A randomized clinical trial was performed evaluating the efficacy of 3 brief cognitive‐behavioral techniques: relaxation, distraction, and positive mood interventions for chronic cancer‐related pain.
Journal ArticleDOI

Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer

TL;DR: The 27-item MDASI-OC meets common criteria for validation and reliability and is sensitive to expected changes in symptoms related to differences in disease and treatment status.